Tuesday, October 20, 2015

Gritstone Oncology Finds $102M In First Funding

San Francisco-based Gritstone Oncology, a biopharmaceuticals firm developing cancer immunotherapies, has raised $102M in a Series A financing, the company said today. The funding came from Versant Ventures, The Column Group, Clarus Ventures plus Frazier Healthcare Partners, Redmile Group, Casdin Capital, and Transformational Healthcare Opportunity. Gritstone is focused on novel tumor-specific neo-antigen (TSNA) based immunotherapies, with an initial focus on lung cancer. More information »